Phase 3 EMBARK Study Shows SRP-9001 Does Not Meet Primary End Point.

Published Date: 02 Nov 2023

Comparing SRP-9001 to a placebo over a 52-week treatment period, there was strong evidence of a clinically meaningful benefit across several prespecified functional secondary end points.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Biomarker-Selected Treatment Shows Promise for Bladder Preservation in MIBC

2.

FDA Investigating Blood Cancer Risk With Gene Therapy Skysona

3.

Surviving cancer, still suffering: Survey reveals gaps in follow‑up care

4.

Charles III, King of Kings, is Cancerous.

5.

The Truth About Apple AirPods


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot